Cardiovascular Drugs Market Size - By Drug Class, By Indication, By Route of Administration, By Distribution Channel, Forecast, 2025 - 2034

Cardiovascular Drugs Market Size

The global cardiovascular drugs market was estimated at USD 153.7 billion in 2024. The market is expected to grow from USD 157.8 billion in 2025 to USD 214.9 billion in 2034, at a CAGR of 3.5% during the forecast period. The rise in cardiovascular diseases such as coronary artery disease, heart failure, and hypertension, is a major driver of market expansion. According to the World Health Organization, CVDs are the leading cause of death globally, accounting for over 17.9 million deaths annually. Also, the demand for effective treatments and therapeutics has increased due to increasing adoption of sedentary lifestyles, aging populations, and unhealthy eating habits.
 

The cardiovascular drugs market is growing due to the continuous development of novel drug classes, combination therapies, and personalized medicine approaches. The patients outcome is greatly enhanced due to better lipid-lowering agents, anticoagulants, antiplatelet drugs, beta-blockers and other heart failure medications. In addition, the use of pharmacogenomics along with biomarker-driven therapies improves treatment efficacy by enabling more precise and individualized care plans. Innovative drug delivery systems including extended-release formulations and transdermal patches, also enhance patient compliance and therapeutic effectiveness, thereby contributing to market growth.
 

Key players are actively investing in research and development, leading to the introduction of next-generation cardiovascular drugs with improved safety profiles and minimized side effects. The market is also being fueled by advanced cardiovascular therapies, driven by global strategic partnerships, mergers, and acquisitions among pharmaceutical companies.
 

Further, heart failure remains a major concern, affecting more than 64 million people globally, as reported by the Global Burden of Disease Study. This drives demand for drugs such as beta-blockers, ACE inhibitors, and newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs).
 

The cardiovascular drugs market encompasses pharmaceutical products designed to prevent, manage, and treat heart-related conditions. It focuses on improving patient outcomes for diseases such as hypertension, heart failure, and coronary artery disorders. 
 

Cardiovascular Drugs Market Trends

• The cardiovascular drugs industry is being driven by the rising prevalence of cardiovascular diseases (CVDs) around the globe. The rising global prevalence of CVDs is a primary driver of market growth. According to the World Health Organization (WHO), over 523 million people worldwide were living with CVDs in 2022, emphasizing the need for effective cardiovascular drugs.
   
• Coronary artery disease (CAD), the most common type of CVD, contributes significantly to market expansion. As per the Centers for Disease Control and Prevention (CDC), approximately 5% of adults aged 20 and older in the U.S. have coronary artery disease (CAD). This condition often requires advanced drug therapies such as statins and antiplatelet agents.
   
• Also, the rising prevalence of hypertension, a major cause of heart disease as well as other cardiovascular conditions. The WHO reports that approximately 1.28 billion adults aged 30 to 79 worldwide suffer from hypertension, creating a continuous need for antihypertensive medications.
   
• Therefore, the introduction of new technologies such as fixed-dose combination therapies and personalized medicine based on genetic profiling, are improving treatment efficacy and patient compliance, thereby fueling market development.
   
• Further, the increasing investment by the pharmaceutical industry in the development of novel drug therapeutics contributes to market growth. For instance, in March 2025, Alnylam Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran).
   
• The product is for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality.
   
• Similarly, AFib affects approximately 1% of the global population, with at least 33.5 million people estimated to be impacted. This prevalence greatly impacts the demand for cardiovascular drugs especially anticoagulants and antiarrhythmic drugs.
   
• Moreover, the global incidence of stroke remains high with the World Stroke Organization predicting that the number of new strokes annually in the world is over 12.2 million. As per the World Stroke Organization, 1 in 4 people over the age of 25 will experience a stroke in their lifetime. Such high incidence leads to increased need of thrombolytics and antiplatelet drug use to manage and prevent the strokes.
   
• Government policies to increase access to essential medications for cardiovascular diseases coupled with growing expenditures on healthcare, are accelerating the use of sophisticated cardiovascular therapies in both developed and developing markets.
   

Cardiovascular Drugs Market Analysis

Based on the drug class, the cardiovascular drugs market is segmented into antihypertensives, antihyperlipidemic, anticoagulants, antiarrhythmics, and other drug classes. The antihypertensives segment dominated the market with USD 42 billion in 2021, USD 42.9 billion in 2022 and USD 43.9 billion in 2023.  
 

• The antihypertensives segment holds a significant share because of the increasing prevalence of hypertension worldwide. Hypertension is one of the leading risk factors for heart disease, stroke, and kidney failure.
   
• According to the American Heart Association, nearly half of adults in the U.S. around 122 million individuals have high blood pressure. Globally, the prevalence of hypertension is projected to rise, particularly in low- and middle-income countries, due to lifestyle factors such as poor diet, physical inactivity, and increased stress levels.
   
• Antihypertensive drugs include several classes such as ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, calcium channel blockers, and diuretics. These medications are essential in reducing blood pressure levels, thereby decreasing the risk of associated cardiovascular events.
   
• Further, the need for antihypertensive medications is boosted by the continuously growing elderly population with comorbid obesity and diabetes. For example, the United Nations has reported that people aged above 65 will reach 1.6 billion by 2050 which poses a significant risk of hypertension along with other complications.
   
• In addition, the World Obesity Federation reports that over 1 billion people globally estimated to be living with obesity by 2030, further expected to drive hypertension rates.
   
• Moreover, improvements in the fixed-dose combination therapies increase treatment outcomes and patient adherence, making this drug class a major factor in the growth of the global cardiovascular drugs market.

Based on the indication, the cardiovascular drugs market is divided into hypertension, hyperlipidemia, coronary artery disease, arrhythmia, and other indications. The hypertension segment accounted for a significant market share of 35.2% in 2024.  
 

• The hypertension segment dominates the market due to the increasing global health burden.  
   
• According to the Global Health Metrics, approximately 10.8 million deaths annually are attributed to elevated blood pressure, underlining the urgency of effective treatment solutions.
   
• The management of hypertension is crucial due to its frequent link with more severe diseases such as myocardial infarction, stroke, and kidney failure.
   
• Moreover, the pharmaceutical industry has developed a broad range of antihypertensive agents including monotherapy and combination therapy options tailored to different patient profiles.
   
• The increasing efforts towards improving the effectiveness of the treatment with the introduction of new renin inhibitors and endothelin receptor antagonists. In addition, greater availability of generic antihypertensive medication has made those drugs more accessible in developing countries.
   
• Additionally, the growing initiatives taken by governments and healthcare organizations to encourage routine blood pressure screening and early treatment are further driving growth of the market.
   

Based on the route of administration, the cardiovascular drugs market is divided into oral, parenteral, and other route of administration. The oral segment dominated the market in 2024 and is expected to grow with a significant CAGR of 3.4% over the analysis period.    
 

• The oral route of administration holds the largest share due to its convenience, high patient compliance, and ease of use. Many cardiovascular drugs, such as antihypertensives, anticoagulants, and beta-blockers, are routinely given to patients in the form of oral tablets or capsules which enable long-term treatment compliance.
   
• Moreover, progress in drug formulation technologies such as sustained-release and extended-release tablets has also shifted therapeutic efficacy towards enhancement and adverse effect avoidance.
   
• The high demand for oral medications is aided by their low cost and broad availability. Pharmaceutical companies continuously working towards achieving better bioavailability and stability of oral drugs, further establishing the dominance of this segment in the market.
   

Based on the distribution channel, the cardiovascular drugs market is segmented into hospital pharmacies, online pharmacies, retail pharmacies, and other distribution channels. The hospital pharmacies segment dominated the market with USD 68.1 billion in 2024 and is expected to reach USD 96.5 billion by 2034.    
 

• The hospital pharmacies segment continues to grow due to high prescription volumes and immediate access to sophisticated medical services in the hospitals.
   
• Both inpatients and outpatients are served by hospital pharmacies, which stock a large number of basic and complex cardiovascular drugs, including emergency medications for acute myocardial infarction, arrhythmias, and heart failure.
   
• These pharmacies play an essential role in the prompt dispensing of life-saving medications and specialty formulations that are not available in retail pharmacies.
   
• Moreover, the specialized nature of hospital pharmacy practice aids in the correct administration, supervision, and management of medication dosages, which improve patient outcomes.
   
• This segment is also fueled by continuing rising admissions to hospitals due to cardiovascular emergencies and increased global investment into healthcare infrastructure.

North America held the largest market share of 41.2% in 2024 in the global cardiovascular drugs market, and it is anticipated to expand at a 3.2% CAGR over the forecast period. The U.S. market was valued at USD 54.2 billion in 2021. The market size was valued at USD 55.4 billion in 2022 and reached USD 56.7 billion in 2023.
 

• The availability of advanced healthcare infrastructure, high healthcare spending and the presence of leading pharmaceutical companies, the U.S. remains a global leader in the cardiovascular drugs market.
   
• According to the American Heart Association, over 48.6% of U.S. adults are affected by some form of cardiovascular disease, creating a sustained demand for effective drug therapies. Additionally, the country spends approximately $417 billion annually on cardiovascular disease-related healthcare, highlighting the growing scale of the market.
   
• Further, the rising prevalence of cardiovascular diseases, such as coronary artery disease and stroke, along with an aging population, continues to drive demand for effective cardiovascular drugs in the U.S. Additionally, government initiatives aimed at improving access to essential medicines and promoting healthcare digitization also support sustained growth.
   

Europe cardiovascular drugs market accounted for USD 41.4 billion in 2024 and is anticipated to show considerable growth over the forecast period.
 

• The market is driven by stringent regulatory frameworks emphasizing early diagnosis and preventive care, along with increased public awareness campaigns. The European Society of Cardiology estimates that cardiovascular diseases are responsible for 3.9 million deaths per year in Europe. This highlights the need for effective treatment solutions.
   
• The increasing use of sophisticated cardiovascular medications in Germany, France, and the U.K. due to their established healthcare systems and favorable reimbursement policies.
   
• Moreover, collaborations between academics, pharmaceutical companies, and other health care institutions continue to drive innovation and improve treatment access which promotes market growth.
   

The Germany cardiovascular drugs market is experiencing robust growth in Europe market.
 

• Germany’s market is driven by a high prevalence of cardiovascular diseases and rapidly growing aging population.
   
• According to the World Health Organization (WHO), cardiovascular diseases account for approximately 36% of all deaths in Germany, making it the leading cause of mortality.
   
• Moreover, strong healthcare infrastructure and widespread health insurance coverage ensure broad access to these drugs. Additionally, increasing health awareness and government initiatives targeting heart health continue to bolster demand.
   

The Asia Pacific cardiovascular drugs market witnessed substantial growth of 4% during the analysis period.
 

• The market of cardiovascular drugs in the Asia Pacific region is expanding rapidly due to increasing prevalence of cardiovascular disease in this region along with improved awareness in the healthcare sector.
   
• Moreover, rapid immigration, lack of physical activity, and the presence of large population base of elderly people results in high burden of CVD in developing countries such as China, India, and Japan.
   
• Further, the increase in initiatives taken through government health programs along with developing healthcare facilities and better insurance policies also aid in the growth of the market.
   
• These regions face a significant treatment gap due to limited access to advanced therapies in rural areas. However, the market holds substantial growth potential due to the high unmet need for effective cardiovascular disease treatment and prevention strategies.
   

China cardiovascular drugs market is poised to witness high growth in the Asia Pacific market over the analysis period.
 

• Government or state programs such as the “Healthy China 2030” campaign are directed toward increasing healthcare availability and addressing non-communicable diseases, including cardiovascular diseases. Such initiatives creates a favorable environment for market growth.
   
• Additionally, the increasing prevalence of hypertension, obesity, and diabetes in China is boosting the demand for cardiovascular medications.
   
• Moreover, the increasing collaborations between local pharmaceutical companies and international firms enhance the availability of high-quality cardiovascular drugs across urban and rural regions, thereby contributing the market growth.  
   

The Saudi Arabia cardiovascular drugs market is witnessing substantial growth in Middle East and Africa market.  
 

• Saudi Arabia is investing in modernization of the healthcare system under the Vision 2030 program, which aims to improve infrastructure and increase local pharmaceutical production. These efforts are positively impacting the availability of cardiovascular medications.
   
• Moreover, the use of highly effective cardiovascular medicaments is required due to increased prevalence of lifestyle-associated cardiovascular risk factors such as smoking, physical inactivity, and unhealthy nutrition. Ongoing digital health policies and public health campaigns contribute to sustained market growth.
   

Cardiovascular Drugs Market Share

The top 5 companies in the cardiovascular drugs industry account for approximately 70% of the market share, including Pfizer, Novartis, AstraZeneca, Bayer, and Johnson & Johnson. These leading pharmaceutical firms focus on developing innovative cardiovascular therapies, such as next-generation anticoagulants, lipid-lowering agents, and combination antihypertensive drugs, to address the growing burden of heart diseases globally. Their robust research and development pipelines emphasize biologics, gene therapies, and personalized medicine approaches to improve patient outcomes and reduce cardiovascular risk factors.
 

Additionally, emerging players such as Lupin, Viatris, and Gilead Sciences are intensifying competition by offering cost-effective generic cardiovascular drugs and expanding their portfolios through biosimilars and new drug delivery technologies. Companies are increasingly engaging in strategic partnerships, mergers, and acquisitions to strengthen their market presence, enhance global distribution networks, and accelerate the commercialization of novel cardiovascular treatments, thereby driving sustained growth in the market.
 

Cardiovascular Drugs Market Companies

Major players operating in the cardiovascular drugs industry are:

• Amgen
• AstraZeneca
• Baxter
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Gilead Sciences
• Johnson & Johnson
• Lupin
• Merck
• Novartis
• Pfizer
• Sanofi
• Viatris
   

Amgen offers innovative cardiovascular therapies such as Repatha (evolocumab), a next-generation PCSK9 inhibitor aimed at significantly lowering LDL cholesterol levels in patients at risk of cardiovascular events. Their pipeline includes biologics targeting lipoprotein(a) reduction, addressing unmet needs in lipid management. Amgen utilizes advanced genomic and real-world data analytics to optimize treatment outcomes and patient stratification.
 

Bayer is a global player in cardiovascular care, offering flagship products such as Xarelto (rivaroxaban), a direct oral anticoagulant widely prescribed for stroke prevention and venous thromboembolism treatment. Their cardiovascular portfolio includes a focus on heart failure and kidney disease-related CVD. Bayer integrates digital therapeutics platforms to support patient adherence and remote monitoring.
 

Novartis leads in cardiovascular innovation with products such as Entresto (sacubitril/valsartan), which revolutionized heart failure treatment. The company also utilizes advanced data platforms integrating real-world evidence to refine cardiovascular treatment protocols and support value-based healthcare initiatives globally.
 

Cardiovascular Drugs Industry News

• In March 2025, Bayer announced that the U.S. FDA accepted its supplemental New Drug Application for KERENDIA (finerenone) under Priority Review. The new indication targets patients with heart failure and preserved ejection fraction, strengthening Bayer’s cardiovascular portfolio.
   
• In October 2024, AstraZeneca signed an exclusive license agreement with CSPC Pharmaceutical Group to develop YS2302018, a novel oral small molecule targeting Lipoprotein(a) (Lp(a)) for cardiovascular disease. This strengthens AstraZeneca’s cardiovascular drug pipeline.
   
• In April 2024, Johnson & Johnson announced its acquisition of Shockwave Medical for USD 13.1 billion. The deal enhances J&J’s cardiovascular treatment portfolio, giving access to Shockwave’s intravascular lithotripsy technology aimed at addressing calcified arterial lesions and expanding its cardiovascular intervention market presence.
   
• In February 2024, Bayer strengthened its cardiovascular portfolio by acquiring exclusive rights to acoramidis, a promising drug for treating transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and potentially fatal heart condition. This move enhances Bayer’s position in the cardiovascular drugs market.
   
• In January 2023, Lupin Pharmaceuticals launched the generic version of Sacubitril and Valsartan in India post-patent expiry. Marketed as Valentas and Arnipin, the drugs target heart failure patients, strengthening Lupin's presence in the market.
   
• In April 2022, Bristol Myers Squibb announced FDA approval for Camzyos (mavacamten), the first cardiac myosin inhibitor, to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), aiming to improve functional capacity and symptoms. The approval is based on positive Phase 3 EXPLORER-HCM trial results.
   

The cardiovascular drugs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Antihypertensives
• Antihyperlipidemic
• Anticoagulants
• Antiarrhythmics
• Other drug classes

Market, By Indication

• Hypertension
• Hyperlipidemia
• Coronary artery disease
• Arrhythmia
• Other indications

Market, By Route of Administration

• Oral
• Parenteral
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Online pharmacies
• Retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE